Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims:

1. (PREVIOUSLY PRESENTED) A method of inhibiting adhesion formation during or

following a surgical procedure comprising administering to a patient in need thereof a

the rapeutically effective amount of at least one COX-2 inhibitor, wherein the $\ensuremath{\text{COX-2}}$

inhibitor is not nimesulide.

2. (WITHDRAWN) A method of treating, preventing, or minimizing keloid formation

during or following a surgical procedure comprising administering to a patient in need

thereof a therapeutically effective amount of at least one COX-2 inhibitor.

3. (WITHDRAWN) A method of treating or preventing benign hypertrophic tumors

comprising administering to a patient in need thereof a therapeutically effective amount

of at least one COX-2 inhibitor.

4. (WITHDRAWN) A method of treating, preventing, or minimizing scar formation during

or following a surgical procedure comprising administering to a patient in need thereof a

therapeutically effective amount of at least one COX-2 inhibitor.

5. (WITHDRAWN) A method of treating, preventing, or minimizing contracture formation

during or following implantation of synthetic, autologous, or heterologous implants

comprising administering to a patient in need thereof a therapeutically effective amount

of at least one COX-2 inhibitor.

6. (CANCELLED)

10632592.1 Page 2 of 8

Response Submitted 3/6/2008

 (WITHDRAWN) The method of claim 4 wherein the surgical procedure is cosmetic or by incision.

- (WITHDRAWN) The method of claim 5 wherein the implant is a breast implant, implant used in cosmetic surgery, abdominal implant, urologic implant, or an orthopedic implant.
- (ORIGINAL) The method of claims 1-5 wherein the COX-2 inhibitor is selected from the group consisting of celecoxib, parecoxib, rofecoxib, valdecoxib, meloxicam, and etoricoxib.
- (ORIGINAL) The method of claims 1-5 wherein the COX-2 inhibitor is administered to said patient before surgery.
- (ORIGINAL) The method of claims 1-5 wherein the COX-2 inhibitor is administered by applying to organ surfaces during surgery.
- (ORIGINAL) The method of claims 1-5 wherein the COX-2 inhibitor is administered after surgery.
- (WITHDRAWN) The method of claim 12 wherein the COX-2 inhibitor is administered by use of a suppository.
- 14. (PREVIOUSLY PRESENTED) A method of inhibiting adhesion formation during or following a surgical procedure comprising administering to a patient in need thereof a therapeutically effective amount of celecoxib.
- 15. (WITHDRAWN) A method of treating, preventing, or minimizing keloid formation during or following a surgical procedure comprising administering to a patient in need thereof a therapeutically effective amount of celecoxib.

10632592.1 Page 3 of 8

U.S. Application No.: 10/767,870 Response to Office Action mailed 9/20/2007

Response Submitted 3/6/2008

(WITHDRAWN) A method of treating or preventing benign hypertrophic tumors
comprising administering to a patient in need thereof a therapeutically effective amount
of celecoxib.

- 17. (WITHDRAWN) A method of treating, preventing, or minimizing scar formation during or following a surgical procedure comprising administering to a patient in need thereof a therapeutically effective amount of celecoxib.
- 18. (WITHDRAWN) A method of treating, preventing, or minimizing contracture formation during or following implantation of synthetic, autologous, or heterologous materials comprising administering to a patient in need thereof a therapeutically effective amount of celecoxib.

10632592.1 Page 4 of 8